Docetaxel, Irinotecan, and Carboplatin in Extensive Stage Non-Small Cell Lung Cancer

NCT00264134 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer
Extensive Stage Unresectable

Interventions

DRUG: Docetaxel
DRUG: Irinotecan
DRUG: Carboplatin

Sponsor

Kentuckiana Cancer Institute